Literature DB >> 15793675

[Treatment with leflunomide in rheumatoid arthritis].

K Krüger1, W Bolten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793675     DOI： 10.1007/s00393-005-0694-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  15 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

3.  Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.

Authors:  J R Kalden; D L Scott; J S Smolen; M Schattenkirchner; B Rozman; B D Williams; T K Kvien; P Jones; R B Williams; C Oed; R Rosenburg
Journal:  J Rheumatol       Date:  2001-09       Impact factor: 4.666

4.  Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.

Authors:  S Cohen; G W Cannon; M Schiff; A Weaver; R Fox; N Olsen; D Furst; J Sharp; L Moreland; J Caldwell; J Kaine; V Strand
Journal:  Arthritis Rheum       Date:  2001-09

Review 5.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Authors:  P Emery; F C Breedveld; E M Lemmel; J P Kaltwasser; P T Dawes; B Gömör; F Van Den Bosch; D Nordström; O Bjorneboe; R Dahl; K Horslev-Petersen; A Rodriguez De La Serna; M Molloy; M Tikly; C Oed; R Rosenburg; I Loew-Friedrich
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

7.  Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.

Authors:  J T Sharp; V Strand; H Leung; F Hurley; I Loew-Friedrich
Journal:  Arthritis Rheum       Date:  2000-03

8.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

9.  The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.

Authors:  J R Kalden; M Schattenkirchner; H Sörensen; P Emery; C Deighton; B Rozman; F Breedveld
Journal:  Arthritis Rheum       Date:  2003-06

10.  Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

Authors:  V Mladenovic; Z Domljan; B Rozman; I Jajic; D Mihajlovic; J Dordevic; M Popovic; M Dimitrijevic; M Zivkovic; G Campion
Journal:  Arthritis Rheum       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.